BioEclipse Therapeutics, Inc. — Form D/A
BioEclipse Therapeutics, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D amendment with the SEC on 2019-10-10. The offering totals $11.8M, of which $10.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2019-10-10
- Form: D/A
- Accession: 0001780708-19-000004
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $11.8M
- Amount sold: $10.1M
- Remaining: $1.6M
- Investors: 13
- Date of first sale: 2019-06-07
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-342724
Issuer
- Name: BioEclipse Therapeutics, Inc.
- CIK: 0001780708
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 329 OYSTER POINT BLVD., 3RD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
- Phone: 408.809.1030
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Elona Baum | Director | San Francisco, CA |
| Mark Frohlich | Director | Houston, TX |
| Biao He | Director | San Francisco, CA |
| Pamela Reilly Contag | Director | South San Francisco, CA |
| Gregory Schiffman | Director | Vancouver, WA |
| Catherine Sohn | Director | South San Francisco, CA |
| Benjamin Carter | Executive Officer | Dallas, TX |
| Pamela Reilly Contag | Executive Officer | South San Francisco, CA |
| Stephen Thau | Executive Officer | South San Francisco, CA |
| Pamela Contag | Director | South San Francisco, CA |
| Pamela Contag | Executive Officer | South San Francisco, CA |
Other filings by this issuer (1)
More